fostamatinib and efgartigimod: novel agents in the treatment of itp
Published 1 year ago • 205 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
2:50
time to achieve platelet count response with efgartigimod in patients with persistent/chronic itp
-
0:52
insights from advance iv study: efgartigimod increases platelet counts of patients with itp
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
29:21
haemostasis overview
-
11:01
eltrombopag & paediatric chronic immune thrombocytopenia (itp) l pediatrics updates
-
2:02
how to ace your rheumatology interview
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:38
the management of itp during and after the covid-19 pandemic
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:04
phase i/ii study of a novel bet inhibitor, bms-986158, alone & with ruxolitinib or fedratinib in mf
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
1:32
novel btki strategies in indolent b-cell malignancies: pirtobrutinib for fl and mzl
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
4:48
an insight into the management of cytopenias in mf
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
1:59
novel investigational drugs and promising therapies for immune thrombocytopenia
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml